Evaluating preclinical efficacy

Science Translational Medicine

Volumn 3, Issue 96, 2011, Pages

  Atkinson, Mark A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; MONOCLONAL ANTIBODY; NICOTINAMIDE;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; AUTOIMMUNITY; B LYMPHOCYTE; DISEASE MODEL; DRUG EFFICACY; GENDER BIAS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; NOTE; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLICATION; TREATMENT RESPONSE; ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SCREENING; GENETICS; METABOLISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 80051837898     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002757     Document Type: Note

References (23)

1. S. Makino, K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri, Y. Tochino, Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29, 1-13 (1980).
2. A A Like, L. Butler, R M Williams, M C Appel, E J Weringer, A A Rossini, Spontaneous autoimmune diabetes mellitus in the BB rat. Diabetes 31, 7-13 (1982).
3. M A Bowman, E H Leiter, M A Atkinson, Prevention of diabetes in the NOD mouse: Implications for therapeutic intervention in human disease. Immunol. Today 15, 115-120 (1994).
4. M A Atkinson, E H Leiter, The NOD mouse model of type 1 diabetes: As good as it gets? Nat. Med. 5, 601-604 (1999).
5. P E Beales, T L Delovitch, A. Signore, P. Pozzilli, Standardizing experiments with NOD mice. Autoimmunity 24, 127-129 (1996).
6. L K Shoda, D L Young, S. Ramanujan, C C Whiting, M A Atkinson, J A Bluestone, G S Eisenbarth, D. Mathis, A A Rossini, S E Campbell, R. Kahn, H T Kreuwel, A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126 (2005).
7. J S Skyler, C. Ricordi, Stopping type 1 diabetes: Attempts to prevent or cure type 1 diabetes in man. Diabetes 60, 1-8 (2011).
8. L. Chatenoud, E. Thervet, J. Primo, J F Bach, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 91, 123-127 (1994).
9. D. Bresson, L. Togher, E. Rodrigo, Y. Chen, J A Bluestone, K C Herold, M. Von Herrath, Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116, 1371-1381 (2006).
10. L. Chatenoud, Immune therapy for type 1 diabetes mellitus - What is unique about anti-CD3 antibodies? Nat. Rev. Endocrinol. 6, 149-157 (2010).
11. C. Greenbaum, M A Atkinson, Persistence is the twin sister of excellence: An important lesson for attempts to prevent and reverse type 1 diabetes. Diabetes 60, 693-694 (2011).
12. U. Klueh, Z. Liu, B. Cho, T. Ouyang, B. Feldman, T P Henning, M. Kaur, D. Kreutzer, Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol. Ther. 8, 402-412 (2006).
13. J B Matthews, T P Staeva, P L Bernstein, M. Peakman, M. Von Herrath; ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group, Developing combination immunotherapies for type 1 diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin. Exp. Immunol. 160, 176-184 (2010).
14. M A Atkinson, It's time to consider changing the rules: The rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 60, 361-363 (2011).
15. B O Roep, M. Atkinson, M. Von Herrath, Satisfaction (not) guaranteed: Re-evaluating the use of animal models of type 1 diabetes. Nat. Rev. Immunol. 4, 989-997 (2004).
16. B O Roep, M S Atkinson, Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia 47, 1650-1656 (2004).
17. E H Leiter, M. Von Herrath, Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal. Diabetologia 47, 1657-1660 (2004).
18. J A Bluestone, K. Herold, G. Eisenbarth, Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464, 1293-1300 (2010).
19. L D Shultz, F. Ishikawa, D L Greiner, Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
20. S. Jaiswal, T. Pearson, H. Friberg, L D Shultz, D L Greiner, A L Rothman, A. Mathew, Dengue virus infection and virus-specifi c HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS ONE 4, e7251 (2009).
21. null mice are susceptible to lethal Salmonella Typhi infection. Proc. Natl. Acad. Sci. U.S.A. 107, 15589-15594 (2010).
22. T. Willinger, A. Rongvaux, H. Takizawa, G D Yancopoulos, D M Valenzuela, A J Murphy, W. Auerbach, E E Eynon, S. Stevens, M G Manz, R A Flavell, Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. U.S.A. 108, 2390-2395 (2011).
23. Competing interests: The author serves in an advisory role for the following companies: Genzyme, Diamyd, Amylin, GSK, Tolerx, and Diakine. Acknowledgments: The author thanks M. Parker for his remarkable eff ort in gathering the material in Table 1 and D. Schatz, C. Wasserfall, T. Brusko, and M. Haller for critical discussions leading to this manuscript. Funding: This views expressed here were developed, over time, with funding from NIH, JDRF, American Diabetes Association, Brehm Coalition for Type 1 Diabetes Research, and Jeff rey Keene Family Professorship.